Evidence map›Paper›PMID 40248418›Full record

ArticleAIMS public health2025

Barriers and facilitators to prescribing buprenorphine for treating opioid use disorder among emergency department and other practice setting physicians.

James A Swartz, Dana Franceschini, Nora M Marino, Adrienne H Call, Lisa Rosenberger, Sarah Whitehouse

Abstract read
In one paragraph

Article in AIMS public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

James A SwartzJane Addams College of Social Work, University of Illinois Chicago, 1040 W. Harrison St., MC (309), Chicago IL 60607, USA.
Dana FranceschiniJane Addams College of Social Work, University of Illinois Chicago, 1040 W. Harrison St., MC (309), Chicago IL 60607, USA.
Nora M MarinoNational Opinion Research Center at the University of Chicago, 55 East Monroe St, 30th Floor, Chicago IL 60603, USA.
Adrienne H CallNational Opinion Research Center at the University of Chicago, 55 East Monroe St, 30th Floor, Chicago IL 60603, USA.
Lisa RosenbergerNational Opinion Research Center at the University of Chicago, 55 East Monroe St, 30th Floor, Chicago IL 60603, USA.
Sarah WhitehouseNational Opinion Research Center at the University of Chicago, 55 East Monroe St, 30th Floor, Chicago IL 60603, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite federal legislation intended to increase the prescribing of buprenorphine as medication for opioid use disorder (MOUD), such as the Drug Addiction Treatment Act (DATA) of 2000, most providers have continued to prescribe to some patients or to not prescribe at all. We aimed to determine the continuing barriers and supports needed for expanding buprenorphine prescribing and compared barriers experienced by emergency department (ED) physicians with those in other practice settings, given the unique aspects of the ED practice setting. We obtained survey data from August through November 2021 from 412 X-waivered Illinois physicians licensed to prescribe buprenorphine as MOUD, 95 (23.1%) of whom worked primarily in a hospital-based ED. Survey questions included: 1) Professional background, practice characteristics, and prescribing practices; 2) barriers to prescribing buprenorphine; 3) barriers to expanding prescribing; and 4) training/additional supports needed to facilitate buprenorphine prescribing. We used bivariate crosstabulations and multivariable OLS and binary logistic regressions to compare the responses of physicians practicing in the ED versus other practice settings and to compare physicians who prescribed buprenorphine in the past year with those who had not. There were few statistically significant differences among the examined subgroups indicating general agreement regardless of practice setting and prescribing status. The most frequently perceived barrier was having an inadequate community-based behavioral health treatment system to which OUD patients could be referred. Insurance reimbursement, difficulties building practice- and community-based systems to support buprenorphine prescribing, and challenges knowing where and how to refer patients for follow-up and ongoing support services were also prominent concerns. Based on study findings, efforts to expand buprenorphine for OUD might focus on providing support to make and manage treatment referrals and expanding the availability of community-based behavioral healthcare services. Building networks of care could potentially have a greater impact on MOUD availability than increasing the number of practitioners trained to prescribe buprenorphine.

Indexed as

buprenorphineDrug Addiction Treatment Actemergency departmentMATmedication for opioid use disordersopioid-related overdosesX-waiver

Identifiers

PMID40248418
PMCPMC11999815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.